← FDA DRUG APPROVALS

FDA ANDA · ANDA090901

PANTOPRAZOLE SODIUM

Sponsor: JUBILANT GENERICS

APPLICATION
ANDA090901
TYPE
ANDA
ORIGINAL APPROVAL
2011-08-30
LATEST ACTION
2020-02-04
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Discontinued

Products

PANTOPRAZOLE SODIUMDiscontinued
PANTOPRAZOLE SODIUM EQ 40MG BASE · TABLET, DELAYED RELEASE · ORAL
PANTOPRAZOLE SODIUMDiscontinued
PANTOPRAZOLE SODIUM EQ 20MG BASE · TABLET, DELAYED RELEASE · ORAL

Approval history

2020-02-04Labeling · Supplement 17 · standardAP
2020-02-04Labeling · Supplement 15 · standardAP
2020-02-04Labeling · Supplement 22 · standardAP
2015-12-07Labeling · Supplement 12 · standardAP
2014-12-21Labeling · Supplement 8 · standardAP
2014-12-21Labeling · Supplement 9 · standardAP
2013-05-30Labeling · Supplement 5 · standardAP
2012-10-16Labeling · Supplement 4 · standardAP
2012-10-16Labeling · Supplement 2AP
2012-10-16Labeling · Supplement 3 · standardAP
2011-08-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →